Furthermore, after the identification of an FDA-approved inhibitor of the NLRP3-specific regulatory protein Bruton ́s tyrosine kinase (BTK), the application of the commercially available BTK inhibitor ibrutinib in severe COVID-19 cases was investigated. This evidence concerns the gene BTK and COVID-19.